George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlant Health Regulatory News (PHC)

Share Price Information for Plant Health (PHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.82
Bid: 3.70
Ask: 3.94
Change: 0.01 (0.26%)
Spread: 0.24 (6.486%)
Open: 3.81
High: 0.00
Low: 0.00
Prev. Close: 3.81
PHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wilbur Ellis Agreement

14 Jun 2023 07:00

RNS Number : 6732C
Plant Health Care PLC
14 June 2023
 

14 June 2023

 

Plant Health Care plc

 ("Plant Health Care" or the "Company")

 

Plant Health Care® ("PHC") and Wilbur-Ellis® Agribusiness Announce Distribution Agreement to Support First OBRONATM Commercial Sales in the U.S.

 

Plant Health Care® (AIM.PHC.L), a leading provider of peptides for plant protection to global agriculture markets, is pleased to announce it has concluded a distribution agreement ("The Agreement") with Wilbur-Ellis® Agribusiness, one of the largest U.S. retailers of agricultural products. The Agreement will support commercial sales of OBRONATM, a foliar fungicide recently approved by US EPA which is expected to be available within key US markets during the summer of 2023. Obrona is a unique product developed to help growers control a wide range of fungal and bacterial plant pathogens within fruits, nuts, vegetables, and row crops.

 

Plant Health Care and Wilbur-Ellis have been working together in an exclusive partnership since 2020 to evaluate and develop PHC279, the active ingredient in OBRONA, for high value specialty and row crop markets. Multiple years of field trials have validated product efficacy to support initial launch focused on corn diseases, such as tar spot (Phyllachora maydis), Gray leaf spot (Cercospora zeae-maydis), and common rust (Puccinia sorghi), as well as powdery and downy mildew and various other diseases in grapes, as well as white mold (Sclerotinia sclerotiorum) and other diseases affecting leafy vegetables within key Western US states.

 

Derived from naturally occurring proteins, PHC279 is the first product from the Company's PREtec technology platform (Vaccines for Plants™) that will be available to US farmers. PREtec stimulates crop growth and enhances crop resistance to fungal and bacterial diseases and improves crop quality and yield. The Company's initial PREtec product, Saori® is successfully being used in Brazil as a seed treatment to control an array of soybean diseases including Asian Soybean Rust (Phakopsora spp.).

 

PREtec provides growers with a novel and environmentally friendly approach to growing crops and is compatible with mainstream agricultural practices. As part of an integrated pest management program, OBRONA will reduce reliance on older synthetic pesticides and will provide growers with a valuable tool to proactively manage disease resistance. The availability of OBRONA will support farmers seeking to use more sustainable and environmentally friendly practices while continuing to provide safe, abundant, and high-quality food.

 

Plant Health Care continues to expand into new markets around the world through strategic partnerships with major global distribution partners. The Company is on track to achieve revenue of $30 million by 2025, through the launch of new products and continued growth through current and future distributor relationships, and to achieve cash breakeven and profit along that track.

 

Jeff Tweedy, CEO of Plant Health Care, said: ‟Having worked with Wilbur-Ellis on the development of OBRONA for more than three years, I am gratified that this new agreement will bring OBRONA to the market to enable control of many of the most recalcitrant fungal and bacterial pathogens challenging growers today. OBRONA will support sustainable agriculture with better crops delivering higher yield for thousands of U.S. farmers."

 

 

Scott Addy, Wilbur-Ellis Agribusiness VP Branded Technologies and Biological Solutions, said: "We are pleased that our partnership with Plant Health Care has resulted in the approval of OBRONA and are looking forward to launching the product this summer to deliver value to the grower in a sustainable way. We expect that there will be many other products that follow, and we will continue to offer our growers biological options to solve their pest issues."

 

 

# # #

 

 

About Plant Health Care

Plant Health Care offers products to improve the health, vigour and yield of major field crops such as corn, soybeans, potatoes, and rice, as well as specialty crops such as fruits and vegetables. We operate globally through subsidiaries, distributors and supply agreements with major industry partners. Our innovative, patent-protected biological products help growers to protect their crops from stress and diseases, and to produce higher quality fruit and vegetables, with a favourable environmental profile.

 

Find out more at www.planthealthcare.com

 

About the Wilbur-Ellis Companies 

 

Founded in 1921, the Wilbur-Ellis companies are leading marketers, distributors and manufacturers of agricultural products and animal nutrients. By developing strong relationships, making strategic market investments, and capitalizing on new opportunities, the Wilbur-Ellis companies have continued to grow the business with sales of over $3.5 billion. For more information, please visit www.wilburellis.com

 

For further information, please contact: 

Plant Health Care plc Jeff Tweedy, CEO

Tel: +1 919 926 1600

Cenkos Securities plc - Nomad & Broker Neil McDonald / Pete Lynch

Tel: +44 (0) 131 220 9771

SEC Newgate (Financial Communications) Robin Tozer / George Esmond / Harry Handyside

Tel: +44 (0)7540 106 366 Email: phc@secnewgate.co.uk

For further information about Wilbur-Ellis, please contact:

Jeanne Forbis, email:jforbis@wilburellis.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEASKLFDLDEEA
Date   Source Headline
22nd Apr 20247:00 amRNSApproval of Harpinαβ in Belgium
16th Apr 20247:00 amRNSPlant Health Care--China Distribution with AMVAC
4th Apr 20247:00 amRNSApproval of PHC68949 in Mexico
4th Mar 20241:55 pmRNSHolding(s) in Company
24th Jan 20244:27 pmRNSHolding(s) in Company
2nd Jan 20247:00 amRNSBrazil approves TEIKKOâ„¢
20th Dec 20237:00 amRNSBoard Changes and Grant of Options
19th Dec 20233:34 pmRNSHolding(s) in Company
30th Nov 20231:45 pmRNSHolding(s) in Company
28th Nov 20233:16 pmRNSHolding(s) in Company
27th Nov 20234:03 pmRNSHolding(s) in Company
27th Nov 20231:27 pmRNSHolding(s) in Company
24th Nov 20234:19 pmRNSDirector/PDMR Shareholding
24th Nov 202310:57 amRNSDirector/PDMR Shareholding
23rd Nov 20232:31 pmRNSHolding(s) in Company
22nd Nov 20237:00 amRNSTrading Update
31st Oct 20237:00 amRNSChange of Adviser
20th Oct 20237:00 amRNSHolding(s) in Company
3rd Oct 20236:28 pmRNSPlant Health Care PREtec Product with Agrii UK
28th Sep 20237:00 amRNSNew PREtec Products Announced
27th Sep 20237:00 amRNSUnaudited Interim Results
25th Sep 20237:00 amRNSPREtec Products Submitted for Regulatory Approval
31st Aug 20237:00 amRNSNotice of Results & Investor Presentation
18th Aug 20237:00 amRNSNew Product Regulatory Approval In Brazil
1st Aug 20237:00 amRNSApproval for Sale of Harpin aß Granted in Poland
24th Jul 20237:00 amRNSGrant of Options
12th Jul 202312:27 pmRNSHolding(s) in Company
30th Jun 20235:07 pmRNSNotification of Major Holdings
28th Jun 202312:29 pmRNSHolding(s) in Company
27th Jun 20234:08 pmRNSHolding(s) in Company
27th Jun 20231:08 pmRNSDirector Shareholding
23rd Jun 20237:00 amRNSResult of Fundraising
22nd Jun 20234:35 pmRNSFundraising to raise up to US$3.6 million
14th Jun 20237:00 amRNSWilbur Ellis Agreement
13th Jun 20231:43 pmRNSResult of AGM
30th May 20237:00 amRNSHolding(s) in Company
24th May 20231:12 pmRNSHolding(s) in Company
19th May 20235:55 pmRNSPublication of Annual Report and Notice of AGM
18th May 20237:00 amRNSResult of Consultation
9th May 20237:00 amRNSPHC68949 granted first stage of approval in Brazil
2nd May 20237:10 amRNSResults for the year ended 31 December 2022
12th Apr 20232:33 pmRNSNotice of Results
5th Apr 20235:29 pmRNSHolding(s) in Company
8th Mar 20232:45 pmRNSExercise of Options
2nd Mar 20237:00 amRNSBiofungicide PHC279 Approved by US EPA
1st Mar 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Statement
30th Jan 202312:08 pmRNSSignificant Shareholder
18th Jan 20237:00 amRNSBoard Appointments
12th Jan 20237:00 amRNSNovozymes Distribution Agreement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.